Get started
Author

Kalusing S. Padvi

Observed names: Kalusing Sega Padvi, Kausing Padvi
ORCID: 0009-0004-9715-4539
Observed ORCID: 0009-0004-9715-4539
OpenAlex ID: A5092886637
Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study
2025 · Jian Wang, Feiyang Yuan, et al. · Frontiers in Oncology · 4
PDF
Development of Potential Antidiabetic Agents using 2D and 3D QSAR, Molecular Docking and ADME Properties In-silico Studies of α-amylase Inhibitors
2024 · Kalusing S. Padvi, Aniket P. Sarkate, et al. · Letters in Drug Design & Discovery · 4
Smart Sustainable Biomaterials and Their Recent Advancement for Targeting the Nervous System
2024 · Sonali S. Shinde, Aniket P. Sarkate, et al. · CRC Press eBooks · 2
Understanding Colon Cancer: Causes, Prevention, and Complementary Therapies Including Therapeutic Foods, Beverages, and Meditation
2024 · Mahalakshmi S. Biradar, Shankar Thapa, et al. · Springer eBooks · 2
Design, Synthesis, and Biological Evaluation of Quinoline‐Thiazolinone Hybrids as Potential Anticancer Agents: An Integrated In Silico Study Using Molecular Docking, Molecular Dynamics Simulation, MM/GBSA, and ADME Prediction
2026 · Kalusing Sega Padvi, Sachin S. Bhusari, et al. · ChemistrySelect
Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy
2023 · Aniket P. Sarkate, Shashikant V. Bhandari, et al. · Springer eBooks
Works count: 6
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type